LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

Search

AbbVie Inc

Fechado

SetorSaúde

207.85 2.48

Visão Geral

Variação de preço das ações

24h

Atual

Mín

202.7

Máximo

211.18

Indicadores-chave

By Trading Economics

Rendimento

-1.1B

697M

Vendas

-1.6B

15B

P/E

Médio do Setor

99.402

51.415

EPS

2.65

Rendimento de Dividendos

3.34

Margem de lucro

4.646

Funcionários

57,000

EBITDA

-635M

4.7B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+25.23% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.34%

2.34%

Próximos Ganhos

30 de jul. de 2026

Próxima data de dividendos

15 de mai. de 2026

Próxima data de ex-dividendo

14 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

9.2B

358B

Abertura anterior

205.37

Fecho anterior

207.85

Sentimento de Notícias

By Acuity

16%

84%

98 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

AbbVie Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 12:38 UTC

Ganhos

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 de fev. de 2026, 13:20 UTC

Ganhos

AbbVie 4Q Revenue Rises on Immunology Growth

29 de abr. de 2026, 12:41 UTC

Ganhos

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 de abr. de 2026, 12:23 UTC

Ganhos

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 de abr. de 2026, 11:50 UTC

Ganhos

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 de abr. de 2026, 11:49 UTC

Ganhos

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 de abr. de 2026, 11:48 UTC

Ganhos

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q EPS 39c >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Net $695M >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Rev $15B >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q Adj EPS $2.65 >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 de abr. de 2026, 11:47 UTC

Ganhos

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 de fev. de 2026, 19:38 UTC

Ganhos

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 de fev. de 2026, 16:19 UTC

Ganhos

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 de fev. de 2026, 15:18 UTC

Ganhos

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 de fev. de 2026, 13:18 UTC

Ganhos

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Rev $16.62B >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Net $1.82B >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Adj EPS $2.71 >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 de fev. de 2026, 12:48 UTC

Ganhos

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Comparação entre Pares

Variação de preço

AbbVie Inc Previsão

Preço-alvo

By TipRanks

25.23% parte superior

Previsão para 12 meses

Média 253.94 USD  25.23%

Máximo 294 USD

Mínimo 203 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para AbbVie Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

15

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

180.37 / 195.54Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

98 / 346 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat